It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCYC’s FA Score shows that 0 FA rating(s) are green whileLYRA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCYC’s TA Score shows that 4 TA indicator(s) are bullish while LYRA’s TA Score has 4 bullish TA indicator(s).
BCYC (@Biotechnology) experienced а -7.12% price change this week, while LYRA (@Biotechnology) price change was +3.81% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
BCYC is expected to report earnings on Mar 04, 2025.
LYRA is expected to report earnings on Mar 05, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
BCYC | LYRA | BCYC / LYRA | |
Capitalization | 1.6B | 17.4M | 9,201% |
EBITDA | -153.09M | -74.34M | 206% |
Gain YTD | 37.168 | -95.166 | -39% |
P/E Ratio | N/A | N/A | - |
Revenue | 39.6M | 1.82M | 2,176% |
Total Cash | 961M | 67.5M | 1,424% |
Total Debt | 42.7M | 36.7M | 116% |
BCYC | LYRA | |
---|---|---|
RSI ODDS (%) | 2 days ago90% | 2 days ago87% |
Stochastic ODDS (%) | 2 days ago88% | 2 days ago87% |
Momentum ODDS (%) | 2 days ago80% | 2 days ago77% |
MACD ODDS (%) | 2 days ago86% | 2 days ago89% |
TrendWeek ODDS (%) | 2 days ago84% | 2 days ago80% |
TrendMonth ODDS (%) | 2 days ago88% | 2 days ago77% |
Advances ODDS (%) | 14 days ago87% | 7 days ago81% |
Declines ODDS (%) | 5 days ago84% | 5 days ago88% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago90% |
Aroon ODDS (%) | N/A | 2 days ago88% |
A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RLAY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RLAY could also see price increases.
Ticker / NAME | Correlation To BCYC | 1D Price Change % | ||
---|---|---|---|---|
BCYC | 100% | +0.28% | ||
RLAY - BCYC | 44% Loosely correlated | +0.17% | ||
PHIO - BCYC | 41% Loosely correlated | +3.44% | ||
XNCR - BCYC | 40% Loosely correlated | +1.94% | ||
SRRK - BCYC | 36% Loosely correlated | +1.74% | ||
ORMP - BCYC | 35% Loosely correlated | -1.90% | ||
More |